Ireland
--:--IST
Recruiting Not applicable

Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardiac Surgery

NCT07588230 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-05-16
Last updated
2026-11-09

Condition(s) studied

Heart Valve DiseasePostoperative Pain

Investigational drug(s) / intervention(s)

Serratus Posterior Superior Intercostal Plane Block With BupivacaineSerratus Posterior Superior Intercostal Plane Block With Saline

Serratus Posterior Superior Intercostal Plane Block With Bupivacaine: Participants in this group will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block prior to surgery using 30 mL of 0.25% bupivacaine, in addition to standard general anesthesia and multimodal analgesia.

Serratus Posterior Superior Intercostal Plane Block With Saline: Participants in this group will receive an ultrasound-guided placebo block using 30 mL of normal saline under identical conditions, in addition to standard general anesthesia and multimodal analgesia.

Study summary

This randomized, double-blind, placebo-controlled study aims to evaluate the effect of the serratus posterior superior intercostal plane (SPSIP) block on postoperative pain and opioid consumption in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients aged 18-75 years * ASA physical status I-III * Scheduled for elective minimally invasive cardiac valve surgery via mini-thoracotomy * Able to understand and use the Numeric Rating Scale (NRS) * Provided written informed consent Exclusion Criteria: * Age \>75 years * Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine) * Coagulopathy or ongoing anticoagulant therapy that cannot be discontinued * Infection at the planned block site * Chronic opioid use or chronic pain conditions * Severe pulmonary disease affecting respiratory assessment * Neurological or psychiatric disorders interfering with pain assessment * Emergency surgery * Pregnancy or breastfeeding * Refusal to participate

Primary outcome measure(s)

  • 24-hour cumulative opioid consumption — 24 hours after surgery
    Total opioid consumption within the first 24 hours after surgery, expressed as intravenous morphine milligram equivalents (IV-MME).

Trial sites (1)

FacilityCityRegionStatus
Fatma Acil Diyarbakır Outside of the US Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07588230 on ClinicalTrials.gov ↗ ← All trials in Turkey